Der Thementhread zu BioVaxys Technology

Paper-based reporting has long been the primary method for recording ADEs, but can be limited by under-reporting, poorly documented reporting, and reporting delays.   As a web-based or mobile app for reporting ADEs, TAET offers added value compared to conventional reporting tools.1 Furthermore, BioVaxys intends to explore the potential of offering blinded demographic and disease data to companies with an interest in healthcare analytics and data mining.

James Passin, BioVaxys CEO, stated, "The acquisition of TAETCO provides BioVaxys with a third low-risk near-term revenue generating product, supporting our core business in cancer and viral vaccine development.  In addition to providing a fee-based product for recording clinical study ADE's for CROs and study sponsors, BioVaxys will seek to leverage recent breakthroughs in artificial intelligence by collaborating with one or more players in healthcare data mining to develop insights into correlations between demographics and other factors and ADEs."

Jay Dhaliwal, the Founder and CEO of TAETCo and developer of the TAET application, is a registered pharmacist with capital markets experience.  He holds a Bachelor of Pharmacy from the University of British Columbia, a Bachelor of Science in Biology from the University of Victoria.   Mr. Dhaliwal has agreed to act as consultant to BioVaxys to assist with the commercial development of TAET.

In addition, BioVaxys is pleased to announce that it has also closed a private placement consisting of 5,360,000 common shares at a price of $0.125 per share for gross proceeds of $670,000. All common shares issued pursuant to the private placement will be subject to a statutory hold period of four months and one day. The Company intends to use the proceeds for the private placement of working capital.

1)  Fukushima, A., Iessa, N., Balakrishnan, M.R. et al. Smartphone-based mobile applications for adverse drug reactions reporting: global status and country experience. BMC Med Inform Decis Mak 22, 118 (2022).

About BioVaxys Technology Corp.

Based in Vancouver, BioVaxys Technology Corp. (www.biovaxys.com) is a British Columbia-registered, clinical stage biotechnology company that is developing viral and oncology vaccine platforms, as well as immuno-diagnostics.  The Company is advancing vaccines for SARS-CoV-2, SARS-CoV-1, and a pan-sarbecovirus vaccine based on its haptenized viral protein technology, and is planning a clinical trial of its haptenized autologous cell vaccine used in combination with anti-PD1 and anti-PDL1 checkpoint inhibitors that will initially be developed for Stage III/Stage IV ovarian cancer.  Also in development is CoviDTH®, a diagnostic for evaluating the presence or absence of a T cell immune response to SARS-CoV-2, the virus that causes COVID-19. BioVaxys has two issued US patents, and multiple US and international patent applications related to its cancer vaccines, antiviral vaccines, and diagnostic technologies. BioVaxys common shares are listed on the CSE under the stock symbol "BIOV" and trade on the Frankfurt Bourse (FRA: 5LB) and in the US (OTCQB: BVAXF).

In case you did not see this posted earlier today on Twitter, BioVaxys and partner ProCare Health will be attending the 35th International Papillomavirus Society (IPVC) meeting in Washington DC from April 17-21 2023 where we will attend scientific symposia on developments in HPV---and most importantly---meet US Opinion Leaders to raise awareness of Papilocare ahead of our planned US distribution.  

A total of six (6) scientific abstracts on new Papilocare clinical studies have been accepted for presentation at IPVC:

EFECT OF A MULTI-INGREDIENT CORIOLUS VERSICOLOR-BASED VAGINAL GEL IN A HPV18  PREGNANT WOMAN WITH CIN II/III LESIONS


EFFECTIVENESS OF A MULTI-INGREDIENT CORIOLUS VERSICOLOR-BASED VAGINAL GEL IN HIGH-RISK HPV PATIENTS IN OVER 35- OR 40-YEAR OLD SUBGROUPS

EFFECT OF A CORIOLUS VERSICOLOR-BASED VAGINAL GEL FOR HIGH-RISK HPV CLEARANCE AND CYTO-NORMALIZATION IN A 44-YEAR-OLD PATIENT WITH HR-HPV PERSITENCE OF MORE THAN 10 YEARS

EFFICACY OF A MULTI-INGREDIENT CORIOLUS VERSICOLOR-BASED VAGINAL GEL IN HIGH-RISK HPV INFECTED PATIENTS: RESULTS OF 6 DIFFERENT STUDIES

EFFECTIVENESS OF A MULTI-INGREDIENT CORIOLUS VERSICOLOR-BASED VAGINAL GEL IN HPV  AND HIV  PATIENTS: A PILOT OBSERVATIONAL STUDY

EFFECT OF A CONSERVATIVE MANAGEMENT OF CIN II USING A CORIOLUS VERSICOLOR-BASED VAGINAL GEL: AN OBSERVATIONAL STUDY

IPVC is a major international scientific meeting with extensive exposure among clinicians, and BioVaxys is excited to be here supporting Papilocare.

Thank you!

-The BioVaxys Team